Video

Dr. Meric-Bernstam on the Safety and Efficacy of ZW25 in HER2-Expressing Solid Tumors

Funda Meric-Bernstam, MD, discusses the safety and efficacy of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumors.

Funda Meric-Bernstam, MD, chair of the Department of Investigational Cancer Therapeutics, medical director of the Institute for Personalized Cancer Therapy, The Nellie B. Connally Chair in Breast Cancer, and a professor, Department of Breast Surgical Oncology, Division of Surgery, at The University of Texas MD Anderson Cancer Center, discusses the safety and efficacy of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumors.

In the phase I trial, patients with HER2 amplified gastroesophageal (GEJ) cancer, biliary tract cancer, colorectal cancer (CRC), and other cancers received ZW25 at a dose of 10 mg/kg every week, or 20 mg/kg every 2 weeks. Patients received a median of 4 prior therapies. Notably, 87% of patients with GEJ cancer and 55% of patients with non-GEJ cancer received at least one prior HER2-targeted therapy, says Meric-Bernstam.

According to investigators, no new safety signals were observed. Data presented at the 2019 ESMO Congress demonstrated that the most common treatment-related adverse events were grade ≤2 diarrhea (45%) and infusion-related reactions (28%), says Meric-Bernstam. At the time of data cut-off, the partial response (PR) rate was 34.8% in 46 of 58 evaluable patients. Encouragingly, investigators reported PRs in biliary cancer, CRC, GEJ, as well as other tumor types including endometrial and ovarian cancer.

Related Videos
Jacob Sands, MD
Martin H. Voss, MD
Amitkumar Mehta, MD
Sunil Adige, MD
Nitin Jain, MD
Kimmie Ng, MD, MPH
Marina Chiara Garassino, MD
Elias Jabbour, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Rahul Banerjee, MD, FACP
Seth Wander, MD, PhD